文献速递泌尿生殖与妇科肿瘤放疗

根治性前列腺切除术后挽救性放疗的剂量-效应:系统综述与荟萃分析

The dose-response of salvage radiotherapy following radical prostatectomy: A systematic review and meta-analysis.
PubMed 文献 · Radiother Oncol · 2016-11-15

该系统综述与荟萃分析纳入1996至2015年间71项研究共10034例患者,评估挽救性放疗后无复发生存(RFS)与剂量的关系。结果显示SRT剂量与RFS显著相关,剂量-效应符合S形曲线,TCD50为65.8Gy,每增加1Gy的RFS提升2.0%(95%CI 1.1-3.2),支持剂量递增至>70Gy。

要点

  • SRT剂量与RFS显著相关(p=0.0001),且剂量-效应独立存在。
  • 70Gy的RFS为58.4%,60Gy为38.5%,TCD50为65.8Gy。
  • 每增加1Gy,RFS提升2.0%(95%CI 1.1-3.2),支持SRT>70Gy。

核心结论

  • SRT存在显著剂量-效应,为剂量递增至>70Gy提供2a级证据。
  • 微观病灶存在SRT剂量-效应,支持前列腺癌固有放射抵抗性假说。

研究设计与样本

  • 1996至2015年系统综述与荟萃分析,共71项研究、10034例患者符合纳入标准。
  • RFS统一定义为PSA>0.2ng/mL或高于SRT后最低值。
  • 采用S形曲线客观拟合剂量-效应,并用非参数统计检验显著性。

主要发现

  • SRT剂量(p=0.0001)、SRT前PSA(p=0.0009)、ECE+(p=0.039)和SV+(p=0.046)与RFS显著相关。
  • 统计分析证实SRT剂量-效应的独立性,剔除含ADT的研究系列未改变结果。
  • 剂量-效应良好符合S形曲线(p=0.0001),TCD50为65.8Gy。
  • 70Gy时RFS为58.4%,60Gy时为38.5%。
  • 每1Gy带来2.0%(95%CI 1.1-3.2)的RFS改善,且SRT剂量-效应与局限性疾病根治性RT显著平行。

关键数值与推荐

  • SRT剂量与RFS显著相关(p=0.0001)。
  • SRT前PSA(p=0.0009)、ECE+(p=0.039)、SV+(p=0.046)与RFS显著相关。
  • S形剂量-效应曲线拟合p=0.0001,TCD50为65.8Gy。
  • 70Gy的RFS为58.4%,60Gy为38.5%。
  • 每1Gy的RFS改善为2.0%(95%CI 1.1-3.2)。

临床怎么用

  • 对根治性前列腺切除术后生化复发患者,可考虑挽救性放疗剂量递增至>70Gy。
  • 制定SRT剂量决策时应结合SRT前PSA、ECE状态和SV状态等与RFS相关的因素。

局限性

  • 原文摘要未报告纳入研究的异质性、偏倚风险及随访时长等局限性信息。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE/OBJECTIVES: To date neither the optimal radiotherapy dose nor the existence of a dose-response has been established for salvage RT (SRT). MATERIALS/METHODS: A systematic review from 1996 to 2015 and meta-analysis was performed to identify the pathologic, clinical and treatment factors associated with relapse-free survival (RFS) after SRT (uniformly defined as a PSA>0.2ng/mL or rising above post-SRT nadir). A sigmoidal dose-response curve was objectively fitted and a non-parametric statistical test used to determine significance. RESULTS: 71 studies (10,034 patients) satisfied the meta-analysis criteria. SRT dose (p=0.0001), PSA prior to SRT (p=0.0009), ECE+ (p=0.039) and SV+ (p=0.046) had significant associations with RFS. Statistical analyses confirmed the independence of SRT dose-response. Omission of series with ADT did not alter results. Dose-response is well fit by a sigmoidal curve (p=0.0001) with a TCD50 of 65.8Gy, with a dose of 70Gy achieving 58.4% RFS vs. 38.5% for 60Gy. A 2.0% [95% CI 1.1-3.2] improvement in RFS is achieved for each Gy. The SRT dose-response remarkably parallels that for definitive RT of localized disease. CONCLUSIONS: This study provides level 2a evidence for dose-escalated SRT>70Gy. The presence of an SRT dose-response for microscopic disease supports the hypothesis that prostate cancer is inherently radio-resistant.

来源:Radiother Oncol,查看原文。版权归原作者所有。

引用

  1. King CR. The dose-response of salvage radiotherapy following radical prostatectomy: A systematic review and meta-analysis. Radiother Oncol. 2016. PMID: 27863963. doi:10.1016/j.radonc.2016.10.026

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。